---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016277"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:04:14.853166+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission

## Summary
- Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.
- Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.
- Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.
- Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.
- R&D expenses $8.0M, G&A $4.0M for Q1 2023.

## SEC filing metadata
- accession: 0001493152-23-016277
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016277
- JSON: https://secwatch.observer/filing/0001493152-23-016277.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016277.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported the first quarter of 2023 results: revenue nil, net income Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share, EPS $0.54 loss per common share. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: nil
  - Net income: Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share
  - EPS: $0.54 loss per common share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.